St Jude joins Edwards, Medtronic in TAVI race with European Portico approval
This article was originally published in Clinica
Executive Summary
St Jude Medical has become another of medtech's big players, alongside Edwards Lifesciences and Medtronic, to compete in the fast-growing transcatheter aortic valve implantation (TAVI) market, after CE marking its next-generation valve Portico for sale in Europe. The 23mm valve is indicated for patients with severe aortic stenosis who are considered to be inoperable or high risk for conventional open-heart valve replacement surgery; it is implanted via the transfemoral approach (via the femoral artery in the leg).